Unicycive Therap Stock
StockStockPrice
Frequently asked questions
What is Unicycive Therap's market capitalization?
What is the Earnings Per Share (EPS) for Unicycive Therap?
What are the analyst ratings and target price for Unicycive Therap's stock?
What is the EBITDA for Unicycive Therap?
What is the free cash flow of Unicycive Therap?
What is the 5-year beta of Unicycive Therap's stock?
How many employees does Unicycive Therap have, and what sector and industry does it belong to?
What is the free float of Unicycive Therap's shares?
Financials
Market Cap
$50.31M5Y beta
2.23EPS (TTM)
-$0.284Free Float
88.00MEBITDA (TTM)
-$28.84MFree Cashflow (TTM)
-$21.66MPricing
Analyst Ratings
The price target is $5.30 and the stock is covered by 5 analysts.
Buy
5
Hold
0
Sell
0
Information
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
14
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker